Bank of America Downgrades Novavax to Underperform Citing Growth Concerns

Bank of America lowered its rating on Novavax to Underperform from Neutral, citing mounting questions about the vaccine maker's long-term growth prospects despite recent progress in stabilizing operations. The firm cut its price target to $7 from $9, reflecting growing skepticism about the company's ability to sustain growth in a challenging post-pandemic market.

Analysts acknowledged that Novavax has executed well in recent quarters, slashing operating expenses by roughly two-thirds from pandemic-era highs and shoring up its balance sheet through significant cost reduction measures. However, they warned that key growth drivers remain uncertain and face substantial headwinds that could limit the company's future prospects.

Demand for its COVID-19 shot, Nuvaxovid, is expected to fade as the vaccine targets the JN.1 variant, while the dominant strain in circulation is now NB.1.8.1. This mismatch between vaccine formulation and circulating strains creates significant challenges for maintaining market relevance and sales volume. New clinical studies will likely be needed under the Food and Drug Administration's updated vaccine framework, which requires more rigorous—and costly—trials as new strains emerge.

The heightened regulatory bar could also complicate potential partnerships for Novavax's experimental COVID-19/influenza combination vaccine, the analysts said. While the company has enjoyed a short-term lift amid funding cuts to some mRNA rivals, Bank of America believes the outlook for sustainable growth is limited due to these regulatory and market challenges. The combination of evolving variant targets and increased trial requirements creates a difficult environment for vaccine manufacturers seeking to maintain competitive positioning.

Novavax shares have swung sharply this year as investors weigh the company's retrenchment efforts against a narrowing path for growth in a post-pandemic market. The downgrade reflects broader concerns about the vaccine industry's transition from emergency pandemic response to sustainable commercial operations, particularly for companies that emerged during the COVID-19 crisis and now face the challenge of adapting to normal market conditions.